BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 P&L / Income Statement
Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)
Revenue by Product and Service
Swipe to see the full flow
Chart details
BridgeBio Pharma, Inc. (BBIO) FY2026 YTD Q3 P&L / Income Statement
Income statement for 2026-01-01 through 2026-09-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.
- Total revenues, net
- 791,362,000 US dollars
- Total cost of revenues
- 45,435,000 US dollars
- Gross profit (calculated)
- 745,927,000 US dollars
- Operating expenses (calculated)
- 970,601,000 US dollars
- Loss from operations
- negative 224,674,000 US dollars
- Total other expense, net
- negative 157,039,000 US dollars
- Loss before income taxes
- negative 381,713,000 US dollars
- Provision for (benefit from) income taxes
- 1,229,000 US dollars
- Net loss
- negative 382,942,000 US dollars
- Net product revenue
- 656,382,000 US dollars
- License and services revenue
- 89,537,000 US dollars
- Royalty revenue
- 45,443,000 US dollars
- Restructuring, impairment, and related charges
- 0 US dollars
- Research and development
- 419,590,000 US dollars
- Selling, general and administrative
- 551,011,000 US dollars
Chart connections
- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to BridgeBio Pharma, Inc.: −$372.97 M; to noncontrolling interests: −$9.97 M.

Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG
Product waitlist
Health Check and Teardown for your own company
A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!
